The role of neoadjuvant chemotherapy of triple-negative breast cancer in St. Petersburg City Clinical Oncological Dispensary

The role of neoadjuvant chemotherapy of triple-negative breast cancer in St. Petersburg City Clinical Oncological Dispensary

Introduction. Triple-negative breast cancer (BC) is very aggressive form of breast malignancies with high levels of dissemination, frequent ecurrence and poor survival rate, as compared to other breast cancer subtypes.Aim of the study – development and introduction of optimized treatment strategy of...

Full description

Bibliographic Details
Main Authors:	A. G. Manikhas, R. N. Babeshkin, R. M. Paltuev, G. M. Manikhas
Format:	Article
Language:	Russian
Published:	ABV-press 2016-09-01
Series:	Opuholi Ženskoj Reproduktivnoj Sistemy
Subjects:	breast cancer triple-negative breast cancer neoadjuvant treatment relapse-free survival overall survival taxanes
Online Access:	https://ojrs.abvpress.ru/ojrs/article/view/491

Similar Items

Taxanes in adjuvant and neoadjuvant therapy for breast cancer
by: S. V. Limareva
Published: (2014-08-01)

Development of cytotoxic chemotherapy in metastatic breast cancer with a triple-negative phenotype
by: E V Karabina, et al.
Published: (2016-06-01)

ASSOCIATION OF NKT- AND ACTIVATED CD25<sup>+</sup> PERIPHERAL BLOOD LYMPHOCYTES WITH DISEASE FREE AND OVERALL SURVIVAL OF TRIPLE NEGATIVE BREAST CANCER PATIENTS
by: A. I. Chertkova, et al.
Published: (2020-12-01)

Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases
by: Lin-Yu Xia, et al.
Published: (2020-06-01)

COMPARATIVE ANALYSIS OF DIFFERENT NEOADJUVANT CHEMOTHERAPY REGIMENS FOR TRIPLE-NEGATIVE BREAST CANCER
by: P. V. Krivorotko, et al.
Published: (2017-12-01)

Development and validation of nomograms for predicting overall and breast cancer-specific survival among patients with triple-negative breast cancer
by: Guo LW, et al.
Published: (2018-11-01)

Construction and Validation of Nomograms Predicting Survival in Triple-Negative Breast Cancer Patients of Childbearing Age
by: Xiang Cui, et al.
Published: (2021-02-01)

The use of neoadjuvant chemotherapy in advanced endometrial cancer
by: L. Philp, et al.
Published: (2021-05-01)

NEW ADVANCES IN THE TREATMENT OF BREAST CANCER: THE ROLE EPOTHILONES
by: T. Y. SEMIGLAZOVA, et al.
Published: (2017-06-01)

BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study
by: Yoshimasa Kosaka, et al.
Published: (2020-02-01)

Neoadjuvant Chemotherapy and Surgical Options for Locally-advanced Breast Cancer: A Single Institution Experience
by: Mohamed Abo Elmagd Salem, et al.
Published: (2017-07-01)

The efficacy of neoadjuvant chemotherapy and survival in older patients with stages II to III triple-negative breast cancer
by: Olga O Gordeeva, et al.
Published: (2019-09-01)

Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy
by: Meiying Li, et al.
Published: (2018-01-01)

THE MAIN PARAMETERS OF CELLULAR IMMUNITY IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER: RELATIONSHIP WITH EFFICIENCY OF CHEMOTHERAPY
by: A. I. Chertkova, et al.
Published: (2018-11-01)

Clinical Initial Response of Neoadjuvant Chemotheraphy in Triple Negative, HER-2, and Luminal Types of Breast Cancer in Denpasar (A Preliminary Study)
by: Kristianto Yuli Yarso, et al.
Published: (2012-01-01)

Clinical Initial Response of Neoadjuvant Chemotheraphy in Triple Negative, HER-2, and Luminal Types of Breast Cancer in Denpasar (A Preliminary Study)
by: Kristianto Yuli Yarso, et al.
Published: (2012-01-01)

Clinicopathological Characteristics and Treatment Strategies of Triple-Negative Breast Cancer Patients With a Survival Longer than 5 Years
by: Ning Xie, et al.
Published: (2021-02-01)

The prospects for cisplatin and nab-paclitaxel combination therapy in patients with pre-treated triple-negative breast cancer. Description of the clinical case.
by: L. G. Zhukova, et al.
Published: (2018-07-01)

A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer
by: Bishal Gyawali, et al.
Published: (2021-02-01)

Low expression of WWC1, a tumor suppressor gene, is associated with aggressive breast cancer and poor survival outcome
by: Zhanwei Wang, et al.
Published: (2019-07-01)

The Survival Outcomes of T1aN0M0 Triple-Negative Breast Cancer With Adjuvant Chemotherapy
by: Wen-Fen Fu, et al.
Published: (2020-09-01)

The main markers of the long-term efficiency of neoadjuvant chemotherapy in breast cancer (review of literature)
by: V F Semiglazov, et al.
Published: (2013-12-01)

How Long is It Safe to Wait for Breast Surgery After Completion of Neoadjuvant Chemotherapy?
by: Ma T, et al.
Published: (2021-02-01)

Triple negative breast cancer: 5-year results of combined treatment
by: Valerijus Ostapenko, et al.
Published: (2014-02-01)

The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis
by: Xingfa Huo, et al.
Published: (2021-01-01)

Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trial
by: Knut Jørgen Labori, et al.
Published: (2017-08-01)

Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
by: Jin Sun Lee, et al.
Published: (2020-05-01)

The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis
by: Olga Caramelo, et al.
Published: (2019-03-01)

A Risk Stratification Model for Predicting Overall Survival and Surgical Benefit in Triple-Negative Breast Cancer Patients With de novo Distant Metastasis
by: Zheng Wang, et al.
Published: (2020-01-01)

Systemic Analysis of the Prognosis-Associated Alternative Polyadenylation Events in Breast Cancer
by: Yi Zhang, et al.
Published: (2020-11-01)

Current status and novel directions in triple negative breast cancer patients. Risk factors. Role of the platinum-based chemotherapy
by: Olivia IONESCU, et al.
Published: (2016-06-01)

Relation Between CD8+T Lymphocyte Infiltration and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer
by: KONG Tiandong, et al.
Published: (2021-05-01)

Prognostic Nutritional Index (PNI) in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy as a Useful Prognostic Indicator
by: Li Chen, et al.
Published: (2021-03-01)

Therapeutic Pattern and Progress of Neoadjuvant Treatment for Early Stage Triple-negative Breast Cancer
by: XIU Meng, et al.
Published: (2020-02-01)

Nomogram Predicting Overall Survival of Resected Locally Advanced Rectal Cancer Patients with Neoadjuvant Chemoradiotherapy
by: Song J, et al.
Published: (2020-08-01)

Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer
by: Shen-Bao Hu, et al.
Published: (2019-01-01)

New opportunities to improve of duration and quality of life: eribulin in the treatment of patients with advanced breast cancer
by: T Yu Semiglazova, et al.
Published: (2016-06-01)

Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer
by: Yaping Yang, et al.
Published: (2019-06-01)

Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer
by: Qi Zhao, et al.
Published: (2021-06-01)

Circulating immune cell dynamics in patients with triple negative breast cancer treated with neoadjuvant chemotherapy
by: Sarah Talamantes, et al.
Published: (2020-10-01)